Quarterly ResultMar 30, 2026, 05:01 AM
Eli Lilly Q3 2025 Revenue Up 54% to $17.6 Billion, Raises Full-Year Guidance
AI Summary
Eli Lilly reported strong third-quarter 2025 financial results, with revenue increasing 54% year-over-year to $17.6 billion, driven by volume growth from Mounjaro and Zepbound. The company also raised its full-year 2025 revenue guidance to $63.0-$63.5 billion and EPS guidance to $21.80-$22.50 (reported) and $23.00-$23.70 (non-GAAP), reflecting continued strong demand and pipeline progress.
Key Highlights
- Q3 2025 revenue increased 54% to $17.60 billion.
- Q3 2025 EPS increased to $6.21 (reported) and $7.02 (non-GAAP).
- Full-year 2025 revenue guidance raised to $63.0-$63.5 billion.
- FDA approved Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer.
- Announced new manufacturing facilities in Virginia and Texas, and expansion of Puerto Rico site.